Dextrorotatory fructose 1,6-diphosphate (FDP) is an intermediate product of glycolysis. It regulates several enzymatic reactions in cells by activating phosphofructokinase, pyruvate kinase and lactate dehydrogenase. FDP can act on cell membranes, promote the cell's uptake of circulating potassium and stimulate the production of high-energy phosphate and 2,3-diphosphoglycerol in cells. In addition, FDP can reduce hemolysis of erythrocytes caused by mechanical trauma and inhibit the production of oxygen free radicals caused by chemical stimulation. In COPD patients, supplementation of FDP is beneficial for treatment, especially in strengthening respiratory intensity, which is manifested as an increase in PImax, PaO2 and tolerance.

Dextrorotatory fructose 1,6-diphosphate (FDP) is an intermediate product of glycolysis. It regulates several enzymatic reactions in cells by activating phosphofructokinase, pyruvate kinase and lactate dehydrogenase. FDP can act on cell membranes, promote the cell's uptake of circulating potassium and stimulate the production of high-energy phosphate and 2,3-diphosphoglycerol in cells. In addition, FDP can reduce hemolysis of erythrocytes caused by mechanical trauma and inhibit the production of oxygen free radicals caused by chemical stimulation. In COPD patients, FDP is beneficial for treatment, especially for strengthening respiratory intensity, which is manifested as an increase in PImax, PaO2 and tolerance.

Dextrorotatory fructose 1,6-diphosphate (FDP) is an intermediate product of glycolysis. It regulates several enzymatic reactions in cells by activating phosphofructokinase, pyruvate kinase and lactate dehydrogenase. FDP can act on cell membranes, promote the cell's uptake of circulating potassium and stimulate the production of high-energy phosphate and 2,3-diphosphoglycerol in cells. In addition, FDP can reduce red blood cell hemolysis caused by mechanical trauma and inhibit the production of oxygen free radicals caused by chemical stimulation. In COPD patients, supplementation with FDP can enhance respiratory intensity, which is manifested as an increase in PImax, PaO2 and tolerance.

This product is first converted into 5-fluoro-2-deoxyuridine nucleotide in the body, which inhibits thymine nucleotide synthetase, blocking the conversion of deoxyuridine nucleotide into deoxythymine nucleotide, thereby inhibiting DNA biosynthesis. In addition, by preventing uracil and orotic acid from incorporating into RNA, the effect of inhibiting RNA synthesis is achieved. This product is a cell cycle-specific drug that mainly inhibits S-phase cells.

This product is first converted into 5-fluoro-2-deoxyuridine nucleotide in the body, which inhibits thymine nucleotide synthetase, blocking the conversion of deoxyuridine nucleotide into deoxythymine nucleotide, thereby inhibiting DNA biosynthesis. In addition, by preventing uracil and orotic acid from incorporating into RNA, the effect of inhibiting RNA synthesis is achieved. This product is a cell cycle-specific drug that mainly inhibits S-phase cells.